Two Janus cannabinoids that are both CB2 agonists and CB1 antagonists

Journal of Pharmacology and Experimental Therapeutics

Volumn 360, Issue 2, 2017, Pages 300-311

  Dhopeshwarkar, Amey ^a   Murataeva, Natalia ^a   Makriyannis, Alex ^b   Straiker, Alex ^a   Mackie, Ken ^a  

^a INDIANA UNIVERSITY   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,3 DICHLOROBENZOYL) 5 METHOXY 2 METHYL 3 (2 MORPHOLINOETHYL)INDOLE; ADENYLATE CYCLASE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; RETINA S ANTIGEN; UNCLASSIFIED DRUG; [1 HYDROXY 9 METHOXY 3 (2 METHYLOCTAN 2 YL)BENZO[C]CHROMEN 6 ONE]; 1-(2,3-DICHLOROBENZOYL)-5-METHOXY-2-METHYL-(2-(MOPHOLIN-4-YL)ETHYL)-1H-INDOLE; 3-(1,1-DIMETHYL-HEPTYL)-1-HYDROXY-9-METHOXY-BENZO(C)CHROMEN-6-ONE; CHROMONE DERIVATIVE; CYCLIC AMP; FORSKOLIN; INDOLE DERIVATIVE; INOSITOL PHOSPHATE; MORPHOLINE DERIVATIVE; PHOSPHOPROTEIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; EMBRYO; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HIPPOCAMPUS; HUMAN; HUMAN CELL; MOUSE; NERVE CELL STIMULATION; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; ENZYME ACTIVATION; HEK293 CELL LINE; METABOLISM; NERVE CELL; PROTEIN TRANSPORT;

ANIMALS; ARRESTIN; CHROMONES; COLFORSIN; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; HEK293 CELLS; HIPPOCAMPUS; HUMANS; INDOLES; INOSITOL PHOSPHATES; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MORPHOLINES; NEURONS; PHOSPHOPROTEINS; PROTEIN TRANSPORT; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2;

EID: 85011306622     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.116.236539     Document Type: Article

References (41)

1. Alexander SP (2016) Therapeutic potential of cannabis-related drugs. Prog Neuropsychopharmacol Biol Psychiatry 64:157-166.
2. Anavi-Goffer S, Baillie G, Irving AJ, Gertsch J, Greig IR, Pertwee RG, and Ross RA (2012) Modulation of L-a-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids. J Biol Chem 287:91-104.
3. Arunlakshana O and Schild HO (1959) Some quantitative uses of drug antagonists. Br Pharmacol Chemother 14:48-58.
4. Atwood BK, Wager-Miller J, Haskins C, Straiker A, and Mackie K (2012) Functional selectivity in CB(2) cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB(2) ligands. Mol Pharmacol 81:250-263.
5. Bekkers JM and Stevens CF (1991) Excitatory and inhibitory autaptic currents in isolated hippocampal neurons maintained in cell culture. Proc Natl Acad Sci USA 88:7834-7838.
6. Clayton N, Marshall FH, Bountra C, and O'Shaughnessy CT (2002) CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain 96:253-260.
7. Comelli F, Bettoni I, Colombo A, Fumagalli P, Giagnoni G, and Costa B (2010) Rimonabant, a cannabinoid CB1 receptor antagonist, attenuates mechanical allodynia and counteracts oxidative stress and nerve growth factor deficit in diabetic mice. Eur J Pharmacol 637:62-69.
8. Corcoran L, Roche M, and Finn DP (2015) The role of the brain's endocannabinoid system in pain and its modulation by stress. Int Rev Neurobiol 125:203-255.
9. Costa B, Trovato AE, Colleoni M, Giagnoni G, Zarini E, and Croci T (2005) Effect of the cannabinoid CB1 receptor antagonist, SR141716, on nociceptive response and nerve demyelination in rodents with chronic constriction injury of the sciatic nerve. Pain 116:52-61.
10. Daigle TL, Kwok ML, and Mackie K (2008) Regulation of CB(1) cannabinoid receptor internalization by a promiscuous phosphorylation-dependent mechanism. J Neurochem 106:70-82.
11. Deng L, Guindon J, Cornett BL, Makriyannis A, Mackie K, and Hohmann AG (2015) Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal. Biol Psychiatry 77: 475-487.
12. Deng L, Guindon J, Vemuri VK, Thakur GA, White FA, Makriyannis A, and Hohmann AG (2012) The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB2 receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy. Mol Pain 8:71.
13. Di Marzo V, Stella N, and Zimmer A (2015) Endocannabinoid signalling and the deteriorating brain. Nat Rev Neurosci 16:30-42.
14. Dhopeshwarkar A and Mackie K (2016) Functional Selectivity of CB2 Cannabinoid Receptor Ligands at a Canonical and Noncanonical Pathway. J Pharmacol Exp Ther 358:342-351.
15. Furshpan EJ, MacLeish PR, O'Lague PH, and Potter DD (1976) Chemical transmission between rat sympathetic neurons and cardiac myocytes developing in microcultures: evidence for cholinergic, adrenergic, and dual-function neurons. Proc Natl Acad Sci USA 73:4225-4229.
16. Grundmann M, Tikhonova IG, Hudson BD, Smith NJ, Mohr K, Ulven T, Milligan G, Kenakin T, and Kostenis E (2016) A molecular mechanism for sequential activation of a G protein-coupled receptor. Cell Chem Biol 23:392-403.
17. Gutierrez T, Crystal JD, Zvonok AM, Makriyannis A, and Hohmann AG (2011) Selfmedication of a cannabinoid CB2 agonist in an animal model of neuropathic pain. Pain 152:1976-1987.
18. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, and Rice KC (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87: 1932-1936.
19. Khanolkar AD, Lu D, Ibrahim M, Duclos RI, Jr, Thakur GA, Malan TP, Jr, Porreca F, Veerappan V, Tian X, George C, et al. (2007) Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. J Med Chem 50:6493-6500.
20. Klein Herenbrink C, Sykes DA, Donthamsetti P, Canals M, Coudrat T, Shonberg J, Scammells PJ, Capuano B, Sexton PM, Charlton SJ, et al. (2016) The role of kinetic context in apparent biased agonism at GPCRs. Nat Commun 7:10842.
21. LaBuda CJ, Koblish M, and Little PJ (2005) Cannabinoid CB2 receptor agonist activity in the hindpaw incision model of postoperative pain. Eur J Pharmacol 527: 172-174.
22. Lauckner JE, Hille B, and Mackie K (2005) The cannabinoid agonist WIN55, 212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. Proc Natl Acad Sci USA 102:19144-19149.
23. Levison SW and McCarthy KD (1991) Characterization and partial purification of AIM: a plasma protein that induces rat cerebral type 2 astroglia from bipotential glial progenitors. J Neurochem 57:782-794.
24. LoVerme J, Duranti A, Tontini A, Spadoni G, Mor M, Rivara S, Stella N, Xu C, Tarzia G, and Piomelli D (2009) Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and bodyweight gain in mice. Bioorg Med Chem Lett 19:639-643.
25. Manley PJ, Zartman A, Paone DV, Burgey CS, Henze DA, Della Penna K, Desai R, Leitl MD, Lemaire W, White RB, et al. (2011) Decahydroquinoline amides as highly selective CB2 agonists: role of selectivity on in vivo efficacy in a rodent model of analgesia. Bioorg Med Chem Lett 21:2359-2364.
26. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, and Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-564.
27. Munro S, Thomas KL, and Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61-65.
28. Murataeva N, Mackie K, and Straiker A (2012) The CB2-preferring agonist JWH015 also potently and efficaciously activates CB1 in autaptic hippocampal neurons. Pharmacol Res 66:437-442.
29. Pernía-Andrade AJ, Kato A, Witschi R, Nyilas R, Katona I, Freund TF, Watanabe M, Filitz J, Koppert W, Schüttler J, et al. (2009) Spinal endocannabinoids and CB1 receptors mediate C-fiber-induced heterosynaptic pain sensitization. Science 325: 760-764.
30. Rahn EJ, Deng L, Thakur GA, Vemuri K, Zvonok AM, Lai YY, Makriyannis A, and Hohmann AG (2014) Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery. Mol Pain 10:27.
31. Rahn EJ, Thakur GA, Wood JA, Zvonok AM, Makriyannis A, and Hohmann AG (2011) Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effects. Pharmacol Biochem Behav 98:493-502.
32. Rahn EJ, Zvonok AM, Thakur GA, Khanolkar AD, Makriyannis A, and Hohmann AG (2008) Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats. J Pharmacol Exp Ther 327:584-591.
33. Schild HO (1947) pA, a new scale for the measurement of drug antagonism. Br Pharmacol Chemother 2:189-206.
34. Straiker A and Mackie K (2005) Depolarization-induced suppression of excitation in murine autaptic hippocampal neurones. J Physiol 569:501-517.
35. Straiker A, Wager-Miller J, Hu SS, Blankman JL, Cravatt BF, and Mackie K (2011) COX- 2 and fatty acid amide hydrolase can regulate the time course of depolarizationinduced suppression of excitation. Br J Pharmacol 164:1672-1683.
36. Straiker A, Wager-Miller J, Hutchens J, and Mackie K (2012) Differential signaling in human cannabinoid CB(1) receptors and their splice variants in autaptic hippocampal neurons. Br J Pharmacol 165:2660-2671.
37. Valenzano KJ, Tafesse L, Lee G, Harrison JE, Boulet JM, Gottshall SL, Mark L, Pearson MS, Miller W, Shan S, et al. (2005) Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 48:658-672.
38. Whiteside GT, Gottshall SL, Boulet JM, Chaffer SM, Harrison JE, Pearson MS, Turchin PI, Mark L, Garrison AE, and Valenzano KJ (2005) A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2- selective agonist, GW405833. Eur J Pharmacol 528:65-72.
39. Wilkerson JL, Gentry KR, Dengler EC, Wallace JA, Kerwin AA, Armijo LM, Kuhn MN, Thakur GA, Makriyannis A, and Milligan ED (2012) Intrathecal cannabilactone CB(2)R agonist, AM1710, controls pathological pain and restores basal cytokine levels. Pain 153:1091-1106.
40. Wong SK (2004) A 384-well cell-based phospho-ERK assay for dopamine D2 and D3 receptors. Anal Biochem 333:265-272.
41. Wyllie DJ and Chen PE (2007) Taking the time to study competitive antagonism. Br J Pharmacol 150:541-551.